Method for determining limits of tolerance intervals, method for evaluating a manufacturing process and corresponding computing device - Patents.com

The method addresses the challenge of accounting for technical limits in tolerance interval calculations, providing reliable quality control in manufacturing processes by using transformed probability content to ensure compliance with specification limits in drug delivery devices.

JP7588096B2Active Publication Date: 2024-11-21SANOFI SA(FR)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021569360
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-24
Filing Date
2020-05-25
Publication Date
2024-11-21
Estimated Expiration
2040-05-25

AI Technical Summary

Technical Problem

Existing methods for determining tolerance intervals in manufacturing processes do not adequately account for technical limits, leading to inaccurate assessments of manufacturing quality and process control, particularly in drug delivery devices.

Method used

A method for determining tolerance intervals that considers technical limits by selecting a probability distribution function, determining a cut-off value, and specifying the probability content, allowing for the calculation of tolerance interval limits using transformed probability content, which is simpler and more efficient than complex algorithms.

Benefits of technology

This method provides reliable and efficient determination of tolerance intervals, ensuring manufacturing processes meet specification limits, enhancing quality control and process management in drug delivery devices and other industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588096000067
    Figure 0007588096000067
  • Figure 0007588096000068
    Figure 0007588096000068
  • Figure 0007588096000069
    Figure 0007588096000069
Patent Text Reader

Abstract

A method for determining the limits of a tolerance interval (TI) is disclosed, the method comprising: - providing a plurality of sample values ​​(x), the sample values ​​(x) varying and defining a sample value distribution (306, 602), the sample values ​​(x) being values ​​of a technical parameter associated with sample items of the sample, the sample items being components of a drug delivery device (100), assemblies for a drug delivery device (100), or drug delivery devices (100), the sample items being of the same structure, and the technical parameter being limited by at least one technical limit value; - selecting a probability distribution function (306, 602) depending on the technical parameters and / or sample values ​​(x); - Using the technical limit (308), the cutoff value (ξ) for the probability distribution function (306, 602) is calculated. L , ξ R ) and - specifying the probability content (pc) for the tolerance interval (TI); - providing limits (UTBL, LTBL) of tolerance intervals (TI) for technical parameters based on a transformed probability content 〈image〉, said transformed probability content 〈image〉 being determined by a cut-off value (ξ L , ξ R ) and based on a specified probability content (pc), Includes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a method for determining limits of a tolerance interval, a method for evaluating a manufacturing process, and a corresponding computing device. [Background technology]

[0002] 3, No. 5, pp. 1111-1115, 2003, or later or earlier, i.e. older or newer versions, relate to a method for estimating at least one limit of a tolerance interval valid over the manufacturing process of a device.

[0003] There are tolerance intervals which are restricted on both sides, i.e. two-sided tolerance intervals. However, it is also possible to use tolerance intervals which are restricted only on one side and open on the other side, i.e. one-sided tolerance intervals. Here, "open" can mean that no tolerance values ​​are specified for the technical measures in one direction, i.e. for the upper or lower limit.

[0004] The calculation of tolerance intervals according to Non-Patent Document 1 concerns tolerance intervals of technological parameters that have a distribution function in which in principle all values ​​can lie. However, there are also technological parameters that may have technological limits, either an upper limit that must not be exceeded or a lower limit below which the parameter cannot take on values. For example, force may always be greater than zero. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] ISO (International Organization for Standardization) 16269-6 Statistical interpretation of data - Part 6: Determination of statistical tolerance intervals, 2014 (E) Summary of the Invention [Problem to be solved by the invention]

[0006] It is an object of the present disclosure to provide an improved method for determining the limits of a tolerance interval. The method should preferably take into account the influence of technological limitations on the calculation of the limits of the tolerance interval. Furthermore, an improved method for the evaluation of a manufacturing process is disclosed. A corresponding computer program product, and a computing device for carrying out the method should also be provided. [Means for solving the problem]

[0007] This object is solved by a method according to claim 1. Further embodiments are given in the dependent claims. Furthermore, the object is solved by further methods for determining the limits of a tolerance interval, a method for the evaluation of a manufacturing process, a computer program product and a computing device.

[0008] In one embodiment, the method for determining the limits of the tolerance interval comprises: - a) providing a plurality of sample values, the sample values ​​varying and defining a sample value distribution, the sample values ​​being values ​​of a technological parameter associated with sample items of the sample, the sample items being members of a drug delivery device, assemblies for a drug delivery device, or drug delivery devices, the sample items being of the same construction and preferably manufactured according to the same specifications, and the technological parameter being limited by at least one technological limit value; - b) selecting a probability distribution function depending on the technical parameters and / or sample values; - c) determining cut-off values ​​for the probability distribution function using technical limits; - d) specifying the probability content for the tolerance interval; - e) providing, preferably calculating, a limit of a tolerance interval or at least two limits of a tolerance interval for the technical parameter based on the transformed probability content, the transformed probability content being based on a cut-off value and based on a specified probability content; Includes.

[0009] The order of steps a) to e) can vary. However, steps a) to d) can be performed before step e) which is based on the results of steps c) and d). Step c) is based on the results of step b). Thus, step b) can be performed before step c). The order of steps c) and d) can for example be swapped.

[0010] The method may be a method for determining limits of a tolerance interval, at least one limit of the tolerance interval may be used for technical purposes, in particular for the manufacture of a drug delivery device or a related part or assembly, and / or the statistical tolerances are used for manufacturing quality control and / or monitoring of a drug delivery device or a related part or assembly, in particular by: - f) At least one limit of the tolerance interval can be compared with a limit of a specification interval for a manufactured item having the same structure or the same structural design as the sample item and preferably manufactured in accordance with the same specification, e.g. product specification or manufacturing specification. - g1) Depending on the result of the comparison, the production process of the manufactured product can be started, continued or resumed if at least one limit of the tolerance interval is located or lies within the specification interval for the production, or - g2) Depending on the comparison result, alternatively, the production process of the product may not be started or stopped if at least one limit is outside the specification interval.

[0011] Steps a) to e) may be performed before step f), which may be performed before step g1) or g2).

[0012] The method may be a method for determining limits of a tolerance interval, and at least one limit of the tolerance interval may be used to adjust a manufacturing process, in particular a manufacturing process for the manufacture of a drug delivery or related part or assembly.

[0013] The probability content can be defined, for example, as in ISO16269-6:2014(E), as described in more detail below. The use of transformed probability content is a simple way to take into account technological limitations that affect the effective area of ​​the assumed probability distribution function. In comparison with other methods that try to take into account technological limitations, no transformation of the probability function is necessary, which may lead to questionable results. Furthermore, no complex algorithms, especially iterative algorithms, or even exact integrations, need to be used, both of which may consume a lot of computing power and computing time of digital processors. Furthermore, the results of the proposed method are understandable and suitable for practical applications, especially in the medical device field.

[0014] The same method can be applied to devices other than drug delivery devices, preferably other medical devices or other industrial devices.

[0015] The term "same structure" can refer to the same structure design, e.g., having the same shape, the same mechanical properties, based on the same CAD (computer-aided manufacturing) data, manufactured in the same mold (injection molding) and / or in the same cavity of the injection mold. Products of the same structure can only differ from each other by manufacturing tolerances.

[0016] The member can be a single or separate element. At least two members operatively connected to each other can form an assembly. The drug delivery device can be a device that performs the movements required for a dispensing operation to dispense a drug from a reservoir containing the drug. The drug delivery device can be an injection device and / or can include a reservoir filled with a drug.

[0017] The specifications may be product or manufacturing specifications. The specifications may specify upper and / or lower values ​​that must be observed.

[0018] A sample value distribution, preferably a probability distribution function that is or should be indicative of the underlying sample value distribution, can be selected.

[0019] For univariate (one-dimensional) probability distribution functions only one limit can be provided or calculated. For multivariate (multidimensional) probability distribution functions, if more than one technical limit is involved, it is possible to calculate more than one limit according to the proposed method. An example of a multivariate distribution function is a bivariate distribution function.

[0020] Providing the tolerance limits includes that the calculations can be performed. Alternatively or additionally, a look-up table may be used. Providing can also include that the calculations are performed at any location, i.e., for example, at a different location and / or on a different computing device than that used to provide the probability content and / or the transformed probability content and / or the technical limit values.

[0021] In principle, if an industrial manufacturing process of a device is realised, there may be the following phases: design, fabrication of one or several prototypes, a small series manufacturing process, a medium series manufacturing process and a large series manufacturing process. It may then be desirable to start the next phase when and only if it is clear or likely that the tolerances and other specifications will also be reached in the next phase. The proposed method allows the calculation of the limits of the tolerance interval and can be the basis for a further decision whether to start a further phase or whether to take other actions, i.e. redesign or selection of a different or modified manufacturing method.

[0022] However, even if the manufacturing process of the device has already been performed, the device parameters may be changed, which may affect the already evaluated device parameters, and therefore further evaluation may be required and the proposed method may be applied or reapplied.

[0023] The proposed procedures may be particularly advantageous for admission procedures, since technical limitations are taken into account for the calculation of one or both limits of the tolerance interval. These admission procedures can be performed before government agencies, for example before the FDA in the US.

[0024] A sample value may also be referred to as an observation. A sample may be a random sample from a large number of devices or device members. Alternatively, a sample may include all drug delivery devices, drug delivery device members, or assemblies of drug delivery devices available at the time, for example when only small series are manufactured to prepare an industrial manufacturing process.

[0025] Based on statistical parameters of the sample values, the limits of a tolerance band or interval can be calculated or estimated. The sample values ​​can be determined or measured, where the measurement includes consideration of the international units of the SI (International System of Units) system.

[0026] The sample size can be smaller than the number of devices available or the number of devices to be manufactured in the future, e.g., less than 10 percent, or less than 1 percent, but e.g., more than 0.001 percent. The devised manufacturing process can be, for example, a manufacturing process for a defined period of time, e.g., a day, a week, a month, etc. The number of devices manufactured during the manufacturing period can be more than 100, more than 1000, or more than 10,000 devices. However, the number of devices manufactured can be less than 100 million devices.

[0027] A normal distribution can be assumed for the probability distribution function. This can be tested, for example, using the Anderson-Darling test or another suitable test. An estimated mean value and an estimated standard deviation can then be calculated and used in the proposed method. However, other probability distribution functions can also be used, for example the log-normal distribution function, the Weibull distribution function, the Gumble distribution function, the Fréchet distribution function. It is also possible to use other statistical descriptors, for example the estimated median.

[0028] The specified probability content can refer to a certain fraction or percentage of the total amount of manufactured articles, where the manufactured articles are components of drug delivery devices or other devices, assemblies for drug delivery devices (other devices), or drug delivery devices (other devices) of the same structure as the sample item. This amount of manufactured articles may already have been manufactured or may be manufactured in the future. This amount may be at least 10, 100, or 1000 times greater than the number of samples from which the sample value was obtained.

[0029] The specified probability content is called a percentage according to ISO16269-6:2014(E) and its meaning can be better understood if the confidence value is also taken into account. A confidence level value 1-α can be used which specifies the probability that the tolerance interval which has to be estimated for the technological parameter contains the value of the technological parameter for at least a percentage of the manufactured items specified by the probability content. At least one limit of the tolerance interval can be calculated also using the determined confidence level value. Conversely, the probability that the estimated tolerance interval contains less than said percentage of the manufactured items is α.

[0030] Thus, the sample values ​​may be distributed with technological limits. A mathematical probability distribution function can model the distribution of the sample values. To reflect the technological limits of the sample values, the probability distribution function may need to be truncated at a cutoff value that represents the technological limits.

[0031] At least one descriptive parameter or at least two descriptive parameters of the sample values ​​can be calculated and used to calculate a cut-off value of the probability distribution function. The cut-off value can be determined by mapping or by overlapping of a hypothesized probability distribution function over a histogram of the sample values. This is explained in more detail below with respect to FIG. 3. The statistical descriptive parameters can be the mean and the standard deviation, especially if a normal distribution function is used in the calculation.

[0032] The physical parameter can be one of the following parameters of the drug delivery device: a) dose accuracy, b) dial torque, c) dosing force, d) capping force, e) cap removal force, f) needle shield removal force, g) injection time, h) activation force, i) needle cover cut-off distance, j) needle extension, k) discharge volume or l) assembly force. All of these parameters may be constrained by technical limitations. The proposed method allows the calculation of reliable data for the limits of the tolerance interval, taking into account the technical limitations that these parameters have. However, alternatively, the tolerance interval for other physical parameters can be calculated according to the proposed method, in particular the tolerance interval or at least one tolerance limit for the thickness parameter or the length parameter.

[0033] a) Dose accuracy: Dose accuracy can relate to devices that have only a predefined dose or that allow dialing of different doses. The injection device can be an auto-injector that injects a fixed amount of fluid. Alternatively or additionally, it may be possible to dial or select a dose within a certain range. In the latter case, dose accuracy is a measure of the accuracy with which the dialed dose corresponds to the dispensed dose.

[0034] Doses below 0 ml (millimeters) may not be possible, i.e. technical limitations exist. This may be particularly relevant for 1 IU testing. The International Unit IU relates to the physiological effect of an agent / drug on the human body. The dose accuracy may measure the amount of fluid expelled from the device, in particular from a drug delivery device / injection device. The drug may be insulin or another drug for the treatment of diabetes. Alternatively, the drug may be used for hormone therapy (thyroid) or other treatments. The drug may be a drug from the list below.

[0035] The dose can relate to the amount of drug in the container, e.g. in the cartridge, in the bulge, or in a pre-filled syringe. The dose in the container may be different from the dispensed dose, see k) below.

[0036] b) Dial torque for dialing a dose: An insulin pen or other drug delivery device may include a dose / dial button (actuating member) that is used to select a dose. By rotating the button, the pen mechanism is prepared to expel the selected dose. To rotate the button, a torque is applied and the corresponding torque can be measured or determined in testing. Since there is no mechanism to reverse the dialed dose, the torque is always greater than zero. In some cases, the dose / dial button may be connected to a spring in the pen or device mechanism. In that case, the spring is loaded by rotating the button (actuating member). To load the spring, a torque is applied and the corresponding torque can be measured or determined in testing. Since potential energy is generated by loading the spring, the torque is always greater than zero. When the same dose is dialed, the dial torque is not necessarily the same. However, this dial torque will be within a range defined according to the specification limits.

[0037] c) Dosing force: The dosing force may be required to dispense a dose of drug manually or by an energy storage element, e.g. by means of a spring. Measurements can be made with a 10 N (Newton) counterweight. The dosing force may have to be generated by the user of the drug delivery device or by e.g. a spring. The user may be a child, an elderly person, or a person with limited mobility or dexterity.

[0038] d) Cap attachment force: The cap of the drug delivery device can be fixed to the drug delivery device, for example, by using a snap feature. The cap can cover the needle of the drug delivery device. The cap may have to be replaced after use to prevent injury or disease transmission in case of unintentional contact with the needle of the drug delivery device. The cap attachment force should not be too strong so as to allow weak users, e.g. those with limited mobility or poor dexterity, to attach the cap. On the other hand, it is necessary for the cap to fit snugly to prevent it from being unintentionally removed. The proposed method allows a reliable number of cap attachment forces to be used to estimate whether the device is within the specification limits or not.

[0039] e) Cap removal force: The cap must not be fixed too loosely to prevent it from being removed unintentionally and to prevent a person from being injured by unintentional contact with the needle. On the other hand, the cap must not be fixed too tightly to allow a weak user, e.g. a user with limited mobility or poor dexterity, to remove the cap. The proposed method allows to estimate whether a device is within the specification limits with a reliable number of cap removal forces.

[0040] f) Needle shield removal force: A cap can be removed from an auto-injector or another drug delivery device, the cap including a needle shield. When the cap is removed together with the needle shield, the auto-injector can be in a ready to actuate state. Depending on the device design, the needle shield removal force can be the same as or different from the cap removal force.

[0041] g) Injection Time: Again, this feature may be particularly relevant for auto-injector devices. The user should be able to rely on a constant injection time.

[0042] h) Activation force: This may be the force that the user must exert to activate the delivery of the drug, for example by pressing a button at the proximal end of the drug delivery device or by moving a separate trigger member. This is an important parameter of drug delivery devices. The proposed method allows a reliable estimation of the value of this parameter.

[0043] One type of activation force is the needle cover activation force, which can be associated with an auto-injector device. After the cap / needle shield is removed, the needle is still protected by the needle cover. This is a plastic member that can be pushed back. This is done by pushing the auto-injector against the body. The force required to push back the needle cover is called the needle cover activation force. For some auto-injectors, an activation button may need to be pressed in addition to this. For this reason, it may be useful to determine or measure two different types of activation forces.

[0044] i) Needle cover shut-off distance: this may be particularly relevant for auto-injector devices. The needle of an auto-injector may be protected by a movable needle cover before and after injection. The shut-off force may relate to the shut-off of the proximal axial movement of the movable needle cover after injection. To test the protection, a certain force, for example 50 N (Newtons), may be applied. The distance the needle cover has moved may then be measured. The shut-off may prevent injuries after use of the drug delivery device. Reliable data of the limits of the tolerance interval for this parameter are particularly important.

[0045] The technical lower limit may be 0 mm. More specifically, 0 mm may be the distance when the first contact with the needle cover is detected by the force sensor. The technical upper limit may be defined by the total length of the needle cover extension. However, this may usually be less relevant since the specification limit is much smaller.

[0046] Measuring the blocking distance can be one way of performing this test. Measuring the blocking force can be an alternative way to test the blocking of the needle cover after injection.

[0047] j) Needle Extension: Needle extension can be the distance that the needle extends or is extended from the autoinjector during injection. This extension can be a characteristic of the injection depth. The injection depth can depend on the length of the needle and / or its attachment location.

[0048] k) Dispensed volume: It is not possible to dispense more than is loaded into the container, e.g., cartridge / syringe. Dispensed volume may relate to the success of a medical procedure with the device.

[0049] l) Assembly force: for example for assembling different parts of a housing or assembling a part in a housing, for example connecting two parts together. Assembly forces can be in the range of 10 N (Newton) to 50 N. Assembly of components is usually force controlled. Samples exceeding the limits can be rejected. This results in truncated distributions when statistical analysis of these in-process controls and / or monitoring of parameters is done. An example can be 30 N. This can vary depending on the device / process step. Assembly forces can be an indirect indicator of the overall device function. If the assembly force is too high or too low, this can indicate that something is wrong and that the function of the device may be impaired.

[0050] The parameters listed above can be determined and compared to nominal values ​​with or without SI (International System) units. In particular, the measurement of these parameters, i.e. comparison with SI units, is possible. Thus, it is possible to meet the requirements given in standards related to the SI system.

[0051] Some of the force parameters can be related to a mechanical energy storage device in the medical device, such as a mechanical spring. Examples of mechanical springs that can be used are helical springs, spiral springs, and / or leaf springs. The springs can be tension or compression springs.

[0052] At least one limit of the tolerance interval can be an upper limit that is compared with an upper specification limit of a specification for the manufacturing process of the device that may also be valid for the sample item. A comparison can be made to evaluate the manufacturing process. If at least one tolerance limit is within the specification limits, for example the manufacturing process can be scaled. If at least one tolerance limit is outside the specification limits, additional actions are necessary, for example redesigning the device or using another manufacturing method. The parameter can be a force parameter or another parameter. The technological limit can be a lower limit that truncates the probability distribution function on the left.

[0053] Alternatively, the at least one limit can be a lower limit that is compared with a lower specification limit of the specification for the manufacturing process of the device. The specification can also be valid for sample items. A comparison can be made to evaluate the manufacturing process. Depending on the evaluation result, the above-mentioned actions can be performed. The parameter can be the ejection amount of the drug or the dose accuracy. The technical limit can be an upper limit that truncates the probability distribution function on the right, for example, the maximum amount of the container that contains the drug to be ejected or held in the container.

[0054] The transformed probability content can be calculated using a specified probability content and a value that depends on or is equal to the area of ​​the truncated portion of the probability distribution function, i.e., the value of the cumulative distribution function of the probability distribution function taking into account the cutoff value. The truncated portion can be in a range that starts at negative infinity or a corresponding value and ends at the cutoff value, i.e., there is a left truncation. Alternatively, i.e., in the case of a right truncation, the truncated portion can be in a range that starts at the cutoff value and ends at positive infinity or a corresponding value. Instead of negative infinity and positive infinity, any suitable large number can be used, for example, a number in the range of 100 to 100 million. The area of ​​the truncated portion is a simple and descriptive property that is easy to calculate. The actual probability content can be a linear transformation of the desired or specified probability content. The area of ​​the truncated portion can be subtracted from the specified probability content, and normalization can be performed by dividing the difference through the area of ​​the remaining part of the distribution.

[0055] The actual probability content can be calculated using the specified probability content, the cumulative distribution function of the probability distribution function, and the cutoff value. In the case of lower or left truncation, the actual probability content can be calculated according to: PC act =(pc-F(ξ L ,p)) / (1-F(ξ L ,p)) where pc is the specified probability content, F(ξ L , p) starts at positive infinity or a corresponding value and has a lower truncation value ξ L is the cumulative distribution function of the probability distribution function ending at p is a vector of characteristic or descriptive parameters of the probability distribution function or of an approximation of the characteristic parameters. This is a relatively simple formula that is easy to calculate, for example, using low processing power and time of a digital electronic processor. This can be a first step e1) to provide the limits of the tolerance interval in step e).

[0056] Alternatively, the actual probability content for an upper or right truncation can be calculated according to: PC act =(pc-F(ξ R ,p)) / (F(ξ R ,p)) where pc is the specified probability content, F(ξ R ,p) is the upper truncation value ξ R is the cumulative distribution function of the probability distribution function starting at and ending at positive infinity or a corresponding value, p is a vector of characteristic or descriptive parameters of the probability distribution function or of an approximation of characteristic parameters. This formula is similar to the formula for left truncation and is for example easy to compute. This can be a first step e1) to provide the limits of the tolerance interval in step e).

[0057] In both cases, the characteristic or descriptive parameters can be the mean and / or standard deviation, in particular if a normal distribution function is assumed and used in the calculations. Alternatively, other types of distribution functions may be assumed and used.

[0058] The transformed probability content can be calculated using the specified probability content and the actual probability content by calculating the sum of the specified probability content and the difference between the specified probability content and the actual probability content, for example according to:

number

number

[0059] Thus, the transformation of the specified probability content can be a linear function of the specified or desired probability content and the area of ​​the truncated part or parts. The area of ​​the truncated part depends non-linearly on the truncation threshold, i.e., cutoff value. As a result of the calculation of the transformed probability content, equations (2) and (3) can be obtained, as shown below.

[0060] The transformed probability content can be used to calculate the tolerance limit coefficients used to calculate at least one limit of the tolerance interval. At least one of the descriptive parameters of the probability distribution function can also be used to calculate at least one limit of the tolerance interval. When the probability distribution function is a normal distribution, the calculation of at least one limit of the tolerance interval can be performed according to the following formula:

number

number

number

number

[0061] The descriptive parameters of the probability distribution function may be the same as the descriptive parameters of the cumulative probability distribution of the distribution function. This may be a third step e3) for providing the limits of the tolerance interval in step e).

[0062] The paper "An R package for Estimating Tolerance Intervals" by Derek S. Young, Journal of Statistical Software, August 2010, Volume 36, Issue 5, page 1 to 39, especially section 4.8. (Univariate) normal tolerance intervals, states that in the one-sided setting, i.e., one-sided tolerance intervals, there exists an exact solution for k. If transformed probability content is used, the transformed tolerance limit coefficient

number

number

number

[0063] The device may be a medical device and ISO11608-1 "Needle based injection systems for medical use - Requirements and test methods - Part 1 Needle based injection systems" 2014 or any earlier or later version is met for the calculation of at least one limit of the tolerance interval. Therefore, the current standard may be modified to include future proposed methods. This may allow for the manufacture of the device to a high quality standard.

[0064] A test can be made as to whether it is necessary to calculate the transformed probability content. The following test formula can be used: 3 * s or less

number

number

[0065] If the test formula is satisfied, a transformed probability content can be calculated and used for the calculation of at least one limit of the tolerance interval. Alternatively, if the test formula is not satisfied, only the specified probability content and not the transformed probability content can be used for the calculation of at least one limit of the tolerance interval.

[0066] A further aspect relates to a method for evaluation of a manufacturing process, which includes the same steps as the method for determining the limits of the tolerance interval. Furthermore, at least one limit of the tolerance interval is compared with a limit of a specification interval for a manufactured article having the same structure or the same structural design as the sample item, preferably manufactured according to the same specifications, e.g. product specifications or manufacturing specifications. If at least one limit of the tolerance interval is located or is within the specification interval for the manufacturing, the manufacturing process of the manufactured article can be started, continued or resumed. Alternatively, the manufacturing process of the manufactured article may not be started or stopped if at least one limit is outside the specification interval.

[0067] The method for evaluation of a manufacturing process may use the above-mentioned method for determining the limits of a tolerance interval or an embodiment thereof, and therefore the same technical effects as mentioned above can also be applied to the method for evaluation of a manufacturing process.

[0068] The proposed method can be used for the preparation of an industrial manufacturing process of a device, preferably a medical device. The medical device can be a drug delivery device, and more preferably an injection device, in particular an automatic injector device or a manually actuated injection device. A prototype or a small series can be manufactured, for example less than 100 pieces, less than 500 pieces, or less than 1000 pieces. If at least one limit of the tolerance interval is within the specification interval, the industrial manufacturing process can be started, i.e., for example, the production of more than 1000 pieces or more than 10000 items per year or even more.

[0069] Another aspect relates to a computer program product having computer readable program code portions (instructions) that, when executed on a controller or processor, perform at least one, any selected plurality, or all of the method steps according to the above-mentioned method. Thus, the features, advantages, and technical effects that are valid for the proposed method and its embodiments can also be valid for the computer program product. The computer program product can be used in many industries, for example, medical device manufacturing, automotive industry, semiconductor industry, solar industry, chemical industry, etc. The computer program product can be data stored on a CD (compact disc), a data stream on the Internet, a RAM (random access memory), a ROM (read only memory, such as PROM (programmable ROM), EPROM (erasable PROM) or EEPROM (electrical EPROM)), a magnetic hard disk, an optical disk, a solid state device memory, or other digital memory device.

[0070] Standard statistical software packages can be modified to also calculate the transformed probability content according to one or more of the proposed methods and to calculate at least one limit of the tolerance interval.

[0071] A final aspect relates to a computing device, such as a computer, laptop, smartphone, tablet, etc., comprising: - a processor configured to execute instructions of, for example, a program; - a memory configured to store instructions and to store data used or generated during the execution of the instructions; a first data providing unit, e.g. an input device, preferably configured for inputting data that can be stored in the memory and that can be used during the execution of the instructions; - a second data providing unit, e.g. an output device, preferably configured to output data generated during execution of the instructions; - a computer program product according to the third aspect or a computer program product for calculating a transformed probability content based on a truncation of the probability distribution function used to calculate at least one limit of the tolerance interval; Includes.

[0072] Thus, the features, advantages and technical effects that are valid for the proposed method and its embodiments may also be valid for computing devices.

[0073] The first data providing unit may be an input file or a keyboard, a touch screen, etc. The second data providing unit may be an output file or a monitor, a screen, preferably a touch screen, or another display device.

[0074] The making and use of the presently preferred embodiments are discussed in detail below. It should be understood, however, that the present disclosure provides many applicable concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed are merely illustrative of specific ways to make and use the disclosed concepts, and do not limit the scope of the claims.

[0075] Furthermore, the same reference numbers refer to the same technical features unless otherwise indicated. Insofar as "may" is used in this application, this means the possibility of doing so and the actual technical implementation. The present concepts of the present disclosure are described below with respect to preferred embodiments in a more specific context, namely, a manufacturing process for drug delivery devices. However, the disclosed concepts can also be applied to other contexts and / or configurations, for example, in the manufacturing processes of automobiles, semiconductor products, or chemical products.

[0076] The above has outlined, rather broadly, the features and technical advantages of the embodiments of the present disclosure. Additional features and advantages of the embodiments of the present disclosure, e.g., the subject matter of the dependent claims, are described below. It should be appreciated by those skilled in the art that the disclosed concept and specific embodiments may be readily utilized as a basis for modifying or designing other structures or processes for achieving concepts having the same or similar purposes as those specifically discussed herein. It should also be recognized by those skilled in the art that equivalent structures do not depart from the spirit and scope of the present disclosure, such as as defined by the appended claims.

[0077] For a more complete understanding of the presently disclosed concepts and advantages thereof, reference is now made to the following description taken in conjunction with the accompanying drawings, which are not drawn to scale, in which: [Brief description of the drawings]

[0078] [Figure 1] Drug delivery devices. [Diagram 2] Test setup for drug delivery devices. [Diagram 3] Empirical values ​​measured using test setup device. [Figure 4] A computing device (computer) for calculating the converted tolerance limits. [Diagram 5] A plot of the density function of a given distribution. [Figure 6] Plot of the density function of a given distribution with left truncation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0079] 1 shows a drug delivery device 100 that may include a container retaining member 101. The drug delivery device 100 may include a main housing member 102 that fully or partially houses the container retaining member 101 and includes further parts of the drug delivery device 100. Alternatively, the main housing member 102 may be connected to the container retaining member 101 but may not surround the container retaining member 101 or even may not surround a portion of the container retaining member 101. See dashed lines in FIG. 1.

[0080] Within the main housing member 102 the following may be configured: a piston rod 104 adapted to move the piston of a container within the container holding member 301; - A drive mechanism 106 for the piston rod 104. The drive mechanism 106 may for example comprise an energy storage element, for example a spring, which is manually or automatically loaded during assembly of the drug delivery device or before each use. - an actuation element 108, which is used for initiating the movement of the piston rod 104, for example at the proximal end P, into the container retaining member 101, thereby using the drive mechanism 106. Alternatively, an automatic injection device may be used which is actuated by the axial movement of a moveable needle shield. A cap 112 that can be attached to the main housing member 102 or to another member of the drug delivery device 100. The cap 112 can be an outer cap that can include a smaller inner cap that directly protects the needle 110.

[0081] The drug delivery device 100 can be a single use or a multiple use device. The actuation element 108 can be part of a trigger mechanism that is triggered from a distal end, for example, when the drug delivery device 100 is an automatic injection device.

[0082] The drug can be dispensed from a container through the needle 110 or through a nozzle connectable and / or connected to the distal end D of the drug delivery device 100. The needle 110 can be changed before each use or can be used several times.

[0083] The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.

[0084] As described below, drugs or agents may include at least one API or combinations thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

[0085] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.

[0086] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those found in handbooks such as Rote Liste 2014 (e.g., but not limited to, main groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition.

[0087] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residue can be either a codable amino acid residue or another naturally occurring residue or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, e.g., the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.

[0088] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0089] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0090] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists include, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flatfish), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rexendin -4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C, CM-3, GLP-1 Erigen, ORMD-0901, NN-9924, NN-9926, NN-9927, nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, exenatide-XTEN and glucagon-Xten.

[0091] An example of an oligonucleotide is, for example, mipomersen sodium (Kynamro®), a cholesterol-lowering antisense therapeutic for the treatment of familial hypercholesterolemia.

[0092] Examples of DPP4 inhibitors are vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.

[0093] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.

[0094] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharma- ceutically acceptable salts. An example of a pharma-ceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.

[0095] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., has a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTIs) and / or dual variable region antibody-like binding proteins (CODVs) with crossover binding region orientation.

[0096] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment can include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.

[0097] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues in the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.

[0098] Exemplary antibodies are anti-PCSK-9 mAb (eg, alirocumab), anti-IL-6 mAb (eg, sarilumab), and anti-IL-4 mAb (eg, dupilumab).

[0099] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.

[0100] It will be understood by those skilled in the art that modifications (addition and / or removal) of the various components of the APIs, formulations, devices, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the invention, which encompasses such modifications, and any and all equivalents thereof.

[0101] 2 shows a test setup device 20 for testing at least one parameter of a drug delivery device, in particular the drug delivery device 100. The test setup device 200 includes: - a fixture arrangement 201 that allows vertical movement of some of the members of the test setup device 200; - a motor M for generating a torque for the movement of the movable member; an upper clamping device 202 capable of clamping the distal or proximal end of the device under test; a lower clamping device 204 capable of clamping the other end of the device under test; a control device 206 capable of controlling the movement generated by the motor M; a measurement reporting device 208, for example connected to a force sensor; may include.

[0102] Other parts of the test setup device 200, such as optional scales, power supply units, etc., are not shown.

[0103] The upper clamping device 202 and / or the lower clamping device 204 may be movable relative to one another to generate or exert a force that is applied to a device under test (DUT).

[0104] The test setup device 200 can be used to measure forces related to the drug delivery device 100 or other devices. In the following, it is assumed that the test setup device 200 is used to measure the capping force of the cap 112, see item d) mentioned in the introductory part of this description. The drug delivery device 100 under test can be a device of device type U300max manufactured by the applicant of the present application. However, other device types can also be tested.

[0105] The fully assembled drug delivery device 100 can be clamped in the test setup device 200. The cap 112 can be held by a lower clamping device 204. The proximal end P of the drug delivery device 100 can be held by an upper clamping device 202. However, it is also possible that the cap 112 is held in the upper clamping device 202 and the proximal end of the drug delivery device 100 is held in the lower clamping device 204.

[0106] It is envisioned that the capping force of 19 drug delivery devices 100 will be measured. These drug delivery devices 100 can be prototypes or part of a small series manufacturing process. Alternatively, the devices may be taken from a large series manufacturing process. One example of a test measurement is shown in FIG.

[0107] Figure 3 shows empirical values ​​measured with the test setup device 200 for the cap attachment force of 19 drug delivery devices 100. A horizontal x-axis 300 is used to classify the sampled values ​​x of the cap attachment force of the cap 112 into classes having a width of, for example, 1 N (Newton). These can be classes with class ranges of 0.5 N to 1.5 N (class 1), 1.5 N to 2.5 N, 2.5 N to 3.5 N, 3.5 to 4.5 N, etc. The sample values ​​are placed within seven classes. - Class 2: 4 sample values, from 1.5N~2.5N - Class 3: 2 sample values, from 2.5N~3.5N - Class 4: 3 sample values, from 3.5N~4.5N - Class 5: 5 sample values, from 4.5N~5.5N - Class 6: 1 sample value of 5.5N~6.5N, - Class 7: 2 sample values, from 6.5N~7.5N - Class 8 from 7.5N to 8.5N: 3 sample values.

[0108] The vertical y-axis 302 shows the number of samples in each class. Column 304 represents the frequency of the force values ​​of the capping force. Mean

number

number

[0109] Average

number

[0110] There is a truncation threshold 308, i.e. technological limit TL, below which the capping force cannot occur. The value of threshold 308 is 0N.

[0111] 3 shows the upper tolerance limit 310, UTBL, when truncation due to the technological limit TL is not taken into account. Furthermore, the calculated lower tolerance limit 312, LTBL, when truncation due to the technological limit TL is not taken into account. The upper tolerance limit 310, UTBL and the lower tolerance limit 312, LTBL, define a tolerance interval TI. The lower tolerance limit LTBL is located to the left of the technological limit 308, i.e. it has a smaller value than the technological limit 308.

[0112] The histogram shown in FIG. 3 can be an accurate representation of the distribution of numerical data. It can be an estimate of the probability distribution of a continuous variable. The probability distribution function 306 can be truncated to take into account the technical limit 308 for the calculation of the upper tolerance limit 310. Even when truncation is taken into account, it is assumed that the lower tolerance limit LTBL does not move beyond the technical limit 308. Thus, the tolerance interval TI is a one-sided tolerance interval or tolerance interval TI with only the upper tolerance limit UTBL. In particular, the tolerance interval TI is calculated as one-sided. However, if the distribution is ξ L When truncated at L The value of can be interpreted as the lower limit of the tolerance range.

[0113] To take into account the technical limitations of the calculation of the upper tolerance limit UTBL, the cut-off value ξ L This can be done graphically or by simple arithmetic. In the example, the x-axis is 300 * A further coordinate system can be used having the following structure: x-value zero is where the maximum of the probability distribution function 306 is located, i.e., this is the mean of the x-axis 300

number

number

[0114] Further optional steps, such as calculating the probability distribution function 306 and / or the value ξ, may be performed before further calculations are performed or a standard or modified standard statistical software package may be used. L , may need to be normalized. The purpose of normalization is to make the area constrained under the probability distribution function 306 have a value of 1. This may require compression or expansion in the x-direction and / or scaling in the y-direction. These steps can be done automatically by running corresponding scripts in a statistical software package. Figure 6 shows the truncated probability distribution function 602. The transformed upper tolerance limit UTBL taking into account the technical limits 308 * The steps performed to calculate θ are described below with respect to FIG.

[0115] FIG. 4 shows a computing device 400 (computer) for calculating the converted tolerance limits. The computing device 400 includes: - a processor (Pr) configured to execute instructions for performing the computations specifically disclosed; - a memory (Mem) configured to store instructions and to store data used or generated during the execution of the instructions; an optional input device (In), for example a keyboard, adapted to input data to be stored in the memory (Mem), in particular for inputting sample values ​​x; - an optional output device (Out), for example a display device, configured to output data generated during execution of the instructions; - at least one limit (UTBL, LTBL) of the tolerance interval (TI), in particular the transformed upper tolerance limit UTBL *Or the lower limit of the allowable range LTBL * Based on the truncation of the probability distribution function (306, 602) used to calculate

number

[0116] There may be a connection / bus 410 between the processor Pr and the memory Mem. Further units of the computing unit 400, such as a power supply unit, an optional Internet connection, etc., are not shown but are known to the skilled person. Alternatively, a server-based solution may be used using computing power and / or memory space available in the Internet, provided by other service providers or on a company intranet.

[0117] FIG. 5 shows a plot of the density function 502 of a given distribution with the upper tolerance limit UTBL and the upper specification limit USL. The x-axis 500 shows the value of the sample value x. The y-axis, not shown, is used to display the frequency of each sample value x. In the example shown in FIG. 5, a normal probability distribution function 502 (density function) is used, i.e. a bell curve or a Gaussian curve. The area under the probability distribution function 502 is 1. This is shown by referring to the normal probability distribution function 502, the cumulative distribution function F(x,p), the CDF of the PDF. FIG. 5 shows the upper tolerance limit 504, UTBL. Truncation is not taken into account for the calculation of the upper tolerance limit 504UTBL with the confidence level of 1-α, the probability content or proportion pc, and the vector p containing the descriptive parameters of the normal probability distribution function 502. This calculation is known to those skilled in the art. The upper tolerance limit 504 is below the upper specification limit 506, USL. Therefore, a decision can be made to start the manufacturing process of the drug delivery device 100. However, this determination may be incorrect due to technical limitations 308 not being properly taken into account.

[0118] Figure 6 shows the ξL 6 shows a plot of the probability distribution function (density function) 602 of a given distribution with left truncation at , e.g., 306. The upper tolerance limit UTBL is the transformed probability content

number

number

[0119] FIG. 6 shows an x-axis 600 for sample values ​​x. The y-axis, not shown, relates to the frequency of the respective sample value. A normal probability distribution function 602 (density function), PDF, approximates the histogram of samples of the drug delivery device 100 or other devices mentioned in the description of FIG. 3. A truncation threshold 604 corresponds to the technological limit TL, e.g., the value zero, see also FIG. 3. The area 606 is a function of the cutoff value ξ L or the truncation value ξ L The area 608 corresponds to the value of the cumulative distribution function F at 1−F(ξ L ,p).

[0120] Line 610 is determined by the technological limit 308, i.e., the cutoff value ξ LThe transformed upper tolerance limit 610 when the truncation of the probability distribution function 602 in * . The delta value 612 is shown especially large so that the displacement can be seen. Displacement can also occur in the other direction, i.e., the cutoff value ξ L Depending on the value of UTBL * Note that can be less than UTBL. Line 614 shows an example of a specification upper limit USL.

[0121] Converted upper bound 610, UTBL * is the confidence level 1-α, the transformed probability content

number

number

number

[0122] Converted upper bound UTBL * can be calculated as follows:

[0123]

number

number

[0124] In the case of right truncation of the probability distribution function, a corresponding calculation can be made. In this case, the transformed lower tolerance limit LTBL * can be calculated as follows:

number

number

[0125] In other words, in statistics, in addition to the explanation of Figures 1-6 above, a truncated distribution is a conditional distribution that results from constraining the domain of some other probability distribution. A truncated distribution occurs in real statistics when, for some reason, the range of values ​​is limited to values ​​above or below a given threshold, or to values ​​within a certain range. For example, when the force of removing the cap 112 of the device 100 is measured, this is subject to truncation because the force can only be positive.

[0126] For this reason, several device-related features that are subject to truncation must be evaluated. For example, the ejection volume of the pen device 100 is always non-negative. For this reason, the dose precision distribution is L = 0, and is left truncated. In practice, the truncation of the function is often ignored, since the values ​​actually considered are far enough away from the truncation threshold to be met that it does not have a significant effect on the derived statistics, although it may be significant in some cases.

[0127] In the validation test, it can be defined that the statistical tolerance interval TI is calculated according to ISO16269-6 (statistical interpretation of data - Part 6: Determination of statistical tolerance intervals, 2014(E) or earlier or later versions) and compared with the specification range S. Here, the truncation due to physical limits can be treated as a limit in the specification range. The acceptance criterion is that the tolerance interval TI is part of or identical to the specification range S. A plot of the density function of a normal distribution or another given distribution with an upper tolerance band UTBL and an upper specification limit USL (upper specification limit) is shown diagrammatically in FIG. 5. In this case, UTBL≦USL is obtained, i.e. the tolerance interval TI is part of or identical to the specification limit S. Thus, the acceptance criterion is met.

[0128] In certain cases, one tolerance limit may exceed the physical limit it meets, but it is known that the physical limit can never actually be exceeded. In that case, the violation can be assessed as not actually present. However, there may be an effect on the other side of the tolerance, which can be handled appropriately. Note that this case is different from the case called truncation, i.e., when values ​​below or above the threshold cannot be observed due to technical or physical limitations or characteristics of the measurement system, even though they are actually and theoretically present. The proposed method should not be applied to "truncation", since other calculations can be applied.

[0129] The following formulas are given to facilitate understanding of the invention. However, the invention should not be bound by this or another theory. The values ​​of a given function can be statistically distributed with a given density function or probability distribution function PDF, which can be a mapping of real numbers, for example sample values ​​x, into an interval between 0 and 1, including in particular the limits of the interval. This is known as R nA parameter vector of p elements of f(.;p):R→[0;1], where n is the dimension of the parameter space. Typically, for distributions used for example for medical device 100 or other types of devices, we have n=2. For example, for a normal distribution, the parameter vector p is p=[μ;σ^2] T where "μ" is the predicted value (mean) and σ^2, i.e. the square of the standard deviation σ, is the variance σ^2. T means the transpose of the vector.

[0130] The corresponding distribution function or cumulative distribution function, CDF, is f(·;p):R→[0;1] where "·" is a placeholder. Where:

number

[0131] Furthermore, R n When integrated over the entire definition range of , i.e., the n-dimensional space of real numbers, ∫ R f( ,p)=1 may be valid, where n is a natural number greater than or equal to 1.

[0132] According to the introduction of the standard ISO16269-6:2014(E), in the first sentence: "A statistical tolerance interval is a sample-based estimation interval that can be asserted with a confidence level of 1-α, e.g., 0.95, to contain at least a specified proportion p of items in a population." This definition of the statistical tolerance interval TI is also used in this application. The specified portion p is referred to in this application as the probability content pc.

[0133] Standard ISO16269-6:2014(E) discloses the possibility to calculate the tolerance interval TI, in particular the lower and upper tolerance limits. However, truncation is not taken into account.

[0134] Without loss of generality, in the following the case of left truncation is considered, for which ξ L See FIG. 6, which shows a plot of the density of a given distribution function 602 with left truncation at F(ξ L ,p) (which is the part to the left of the truncation) does not actually exist, L is R's ξ L The upper bound of the tolerance UTBL is intended to be present with the element.

number

[0135] This is because there may be technical limitations308 on the variable x under investigation as described above, so F(ξ L ;p) probability content pc, i.e., truncation ξ L So that the left part 606 of R does not actually exist, L It means that the element exists.

[0136] The upper tolerance limit UTBL indicates that there is a certain probability content pc within the matching tolerance interval TI. However, the portion of the probability content pc that is not actually relevant F(ξ L ;p) is large, the upper tolerance limit UTBL may require some transformation to reflect the truncation of the cumulative density function CDF.

[0137] As mentioned above, the required probability content pc may need to be transformed as shown diagrammatically in FIG.

number

[0138] In the first step, the actual probability content pc act , or the actual probability content pc covered by the tolerance interval TI act For example, this can be calculated using the truncation L This can be corrected by subtracting the matched portion 606 due to the actual probability content pc act can be calculated by a linear transformation of the desired probability content. The truncated part 606 of the distribution function 602 (see the left part of FIG. 6) can be subtracted from the desired probability content pc. Normalization can be done by dividing by the remaining part 608 of the distribution (see the right part of FIG. 6). PC act =(pc-F(ξ L ,p)) / (1-F(ξ L ,p)) Equation (1)

[0139] However, other formulas can be used to calculate the actual probability content pc act You can also ask for:

[0140] In the second step, the transformed probability content

number

number

[0141] However, the transformation function T L Other equations can also be used for (pc). Using equation (1), the conversion function T L (pc)=pc+(pc-pc act ) which gives us the following:

number

number

[0142] Thus, the transformation of the desired probability content pc can be a linear function of the desired probability content pc and the truncated portion 606 of the distribution 602. The area of ​​the truncated portion 606 is determined by the truncation threshold ξ L can depend nonlinearly on

[0143] R n ξ R In the case of right truncation on an element, the matching transformation of the probability content is:

number

[0144] The derivation of the formula for right truncation is a further term transformation and is directly analogous to the left truncation case. This is described in the introduction to this document. act and the formula for right truncation.

[0145] Example: Assume that the force function of the pen device 100 is tested and the distribution of sample values ​​x is known to be normal. A USL of 40 N (Newtons) is defined for the function. Due to physical properties, the force is ξ L = 0N. The acceptance criterion for the test can be that at least pc = 97.5% of the probability content is within the specification limits with a confidence level of 1-α = 95%. As a result of testing 20 samples,

number

[0146] To handle the truncation problem correctly, we can use the technique derived above. Using equation (2), the required probability content transforms to

number

[0147] Then, further using equation (2), we get the following:

number

[0148] In the third step,

number

number

number

number

number

[0149] In the fourth step, the resulting tolerance interval is calculated, i.e., I=[0;26.12]N. The upper bound is also less than the upper specification limit USL of 40N. Hence, the acceptance criterion is met.

[0150]

number

number

[0151] Derek S. Young's paper states that there exists an exact solution for k in the one-sided case. k=1 / sqrt(n)t * n-1;1-alpha (sqrt(n)z P ) Formula (5) where n is the number of samples and t * n-1;1-alpha (Delta) is the (1-α)th quantile of the non-central t-distribution with d degrees of freedom, say n-1, and non-centrality parameter delta, z P is the P-th percentile of the standard normal distribution. Alternatively, the exact solution can be calculated by numerical integration. However, the numerical effort, i.e., processor power, may be much larger compared to using an analytically exact solution.

[0152] The significance of truncation can be seen, for example, in "Prozessfaehigkeit bewerten, Kennzahlen fuer normalverteilte und nicht-normalverteilte Merkmale" June 11th, 2014, http: / / www.drsteuer.de / vorlagen / Prozessfaehigkeit_bewerten_Nov_14.pdf (accessed May 16, 2019) and “Prozessfaehigkeit bei technisch begrenzten Merkmalen, Faehigkeitskennzahlen und Berechnungsmethoden” January 15, 2015, URL: Truncation can be evaluated according to the following rules of Barbara Bredner at https: / / www.bb-sbl.de / wp-content / uploads / 2018 / 08 / BB-SBL-Prozessf%C3%A4higkeit-bewerten-V13-2015-01-15.pdf (accessed 20 May 2013):

number

number

[0153] A further step can be, for example, the analysis of the processing capabilities of truncated distributions, as described in Barbara Bredner, "Processes for the analysis of technically relevant products, processes for the analysis of technically relevant products and methods for the analysis of technically relevant products," January 15, 2015, URL: https: / / www.bb-sbl.de / wp-content / uploads / 2018 / 08 / BB-SBL-Prozessf%C3%A4higkeit-bewerten-V13-2015-01-15.pdf (accessed May 20, 2019).

[0154] In summary, the transformation of probability content required in case of truncated distributions is disclosed. In case of left truncation, the probability content should be transformed according to equation (2) or a similar / corresponding equation. In case of right truncation, the probability content should be transformed according to equation (3) or a similar / corresponding equation.

[0155] It is also possible to transfer the given technical teachings to distributions other than normal distributions, such as log-normal distribution functions, Weibull distribution functions, Gumble distribution functions, Frechet distribution functions, and the like.

[0156] Although the embodiments of the present disclosure and its advantages are described in detail, it should be understood that various changes, substitutions and alterations can be made without departing from the spirit and scope of the present disclosure as defined in the appended claims. For example, it will be readily understood by those skilled in the art that many of the characteristics, functions, processes and methods described herein may vary but remain within the scope of the present disclosure. Furthermore, the scope of the present application is not intended to be limited to the specific embodiments of the systems, processes, products, methods or steps described in the present disclosure. Those skilled in the art will readily appreciate from the disclosure of the present disclosure that systems, processes, manufactures, methods or steps, now existing or later developed, that perform substantially the same functions or achieve substantially the same results as the corresponding embodiments described herein can be utilized in accordance with the present disclosure. Thus, the appended claims are intended to include such systems, processes, methods or steps within their scope. The embodiments described in the first part of this specification can be combined with each other. The embodiments described in the descriptions of Figures 1-6 can also be combined with each other. Furthermore, the embodiments described in the first part of this specification can be combined with the examples in the second part of this specification related to Figures 1-6. [Explanation of symbols]

[0157] 100 Drug delivery device 101 Container holding member 102 Main housing member 104 Piston rod 106 Drive mechanism 108 Actuating Elements 110 needles 112 Cap 200 Test Setup Devices 201 Fixture configuration 202 Upper clamping device 204 Lower Clamping Device 206 Control Device 208 Measurement reporting device 300 x axis 302 y-axis 304 A column representing one class of force values 306 Normal Probability Distribution Function 308 Truncation Threshold 310 Upper limit of allowable width UTBL 312 Calculated Lower Tolerance Limit LTBL 400 Computing Devices 410 Connect Pr Processor Mem Memory In Input Device Out Output device 500 x axis 502 Normal Probability Distribution Function 504 Upper limit of allowable width UTBL 506 Specification upper limit USL 600 x axis 602 Normal Probability Distribution Function 604 Truncation Threshold 606 Area corresponding to the value of cumulative distribution function F 608 Area corresponding to the remaining part of the cumulative distribution function F 610 Upper limit of allowable width UTBL 612 Delta Value 614 Specification upper limit USL TL Technical Limits CDF Cumulative distribution function PDF Probability Distribution Function x the variable under test X the set of x values s, σ Standard deviation of X σ^2 variance (lowercase Greek letter sigma) μ predicted value (lowercase Greek letter mu) S Specification range TI Tolerance Interval DE device evaluation, USL Specification Upper Limit UTBL Upper limit of tolerance UTBL * Converted tolerance limit LSL Lower Specification Limit LTBL Lower Limit 1-α Trust Level (1-lowercase Greek letter alpha) F(·;p) Cumulative distribution function with parameter vector p f(·;p) Probability distribution function (density function) with parameter vector p k tolerance limit coefficient

number

number

number

Claims

1. 1. A method for determining limits of a tolerance interval (TI), comprising: providing a plurality of sample values ​​(x), the sample values ​​(x) varying and defining a sample value distribution (306, 602), the sample values ​​(x) being values ​​of a technical parameter associated with sample items of the sample, the sample items being components of a drug device (100), assemblies for a drug device (100), or drug devices (100), the sample items being of the same structure, and the technical parameter being limited by at least one technical limit value; Selecting a probability distribution function (306, 602) depending on the technological parameters and / or sample values ​​(x); determining cutoff values ​​(ξL, ξR) for the probability distribution functions (306, 602) using technological limits (308); Specifying a probability content (pc) for a tolerance interval (TI), Probability content is the "proportion" in ISO 16269-6:2014(E), Transformed Probability Content [Equation 1] providing limits (UTBL, LTBL) of tolerance intervals (TI) for technical parameters based on the transformed probability content [Equation 2] is based on cutoff values ​​(ξL, ξR) and is based on a specified probability content (pc); The method comprising:

2. A specified probability content (pc) refers to a proportion or percentage of the total amount of a manufactured article, such as a component of a drug delivery device, an assembly for a drug delivery device, or the like. is a drug delivery device (100) of the same structure as the sample item, 10. The method of claim 1, wherein the quantity of manufactured goods is the quantity manufactured or to be manufactured, which is at least 10, 100, or 1000 times greater than the number of samples from which the sample values ​​(x) were obtained.

3. At least one descriptive parameter of the sample value (x) [Equation 3] or at least two descriptive parameters [Equation 4] is calculated, At least one description parameter [Equation 5] or with at least two descriptive parameters [Equation 6] The method of claim 1 or 2, wherein the probability distribution function (306, 602) is determined using:

4. The technical parameters are the following parameters of the drug delivery device (100):

4. The method of claim 1, wherein the parameter is one of dose accuracy, dial torque, dispensing force, cap (112) installation force, cap (112) removal force, needle shield removal force, injection time, activation force, needle cover shutoff distance, needle extension, delivery volume, and assembly force.

5. a) at least one limit of the tolerance interval is an upper limit (UTBL) that is compared with an upper specification limit (USL) of a sample item to evaluate the manufacturing process; or 5. The method of claim 1, wherein the at least one limit is a lower specification limit (LTBL) that is compared with a lower specification limit (LSL) of a sample item to evaluate the manufacturing process.

6. Transformed Probability Content [Equation 7] is calculated using a specified probability content (p c ) and a value determined by or equal to the area of ​​the truncated portion (606) of the probability distribution function (306, 602) or a value determined by or equal to the value of the cumulative distribution function (F) of the probability distribution function (306, 602) taking into account cutoff values ​​(ξ L , ξ R ), 6. The method of claim 1, wherein the truncated portion (606) is within a range starting at negative infinity or a corresponding value and ending at a cutoff value (ξL), or within a range starting at a cutoff value (ξR) and ending at positive infinity or a corresponding value.

7. 7. The method of claim 6, wherein the actual probability content (pcact) is calculated using the specified probability content (pc), the cumulative distribution function (F) of the probability distribution function (306, 602), and the cutoff value (308).

8. Transformed Probability Content [Equation 8] 8. The method of claim 7, wherein is calculated using a specified probability content (pc) and an actual probability content (pcact), preferably by calculating the sum of the specified probability content (pc) and the difference between the specified probability content (pc) and the actual probability content (pcact).

9. Transformed Probability Content [Equation 9] Using the tolerance limit coefficient [Equation 10] is calculated and used to determine the descriptive parameters of the probability distribution function (306, 602) [0011] 9. The method of claim 8, wherein at least one limit (UTBL, LTBL) of the tolerance interval (TI) is calculated by also using at least one of

10. Tolerance limit factor [0012] is for one-sided configuration, Preferably, [0013] is calculated according to where n is a natural number indicating the number of samples, t*n-1; 1-alpha (delta) is the (1-α)th quantile of the non-central t-distribution with d degrees of freedom and non-centrality parameter delta, zP is the Pth percentile of the standard normal distribution, and the transformed probability content (pc-hat) is used for P; 10. The method of claim 9, wherein sqrt() is the square root function.

11. The device (100) is a medical device and conforms to ISO11608-1 "Needle-based injection systems for medical use - The method according to any one of claims 1 to 10, wherein the requirements of "Requirements and test methods - Part 1 Needle based injection systems" 2014 or an earlier or later version are met for the calculation of at least one limit (UTBL, LTBL) of the tolerance interval (TI).

12. The method of any one of claims 1 to 11, wherein at least one limit of the tolerance interval (TI) is used for the manufacture of the drug delivery device (100) or of an associated part or assembly.

13. 13. The method according to claim 12, wherein at least one limit of the tolerance interval (TI) is used for production quality control and / or for monitoring and / or adjusting the production process.

14. A method for determining the limits of a tolerance interval (TI) based on transformed probability content [0014] A test is performed to see if it is necessary to calculate If the test formula is satisfied, the following method for determining the limits of the tolerance interval (TI) is performed: providing a plurality of sample values ​​(x), the sample values ​​(x) varying and defining a sample value distribution (306, 602), the sample values ​​(x) being values ​​of a technical parameter associated with sample items of the sample, the sample items being components of a drug device (100), assemblies for a drug device (100), or drug devices (100), the sample items being of the same structure, and the technical parameter being limited by at least one technical limit value; Selecting a probability distribution function (306, 602) depending on the technological parameters and / or sample values ​​(x); determining cutoff values ​​(ξL, ξR) for the probability distribution functions (306, 602) using technological limits (308); Specifying a probability content (pc) for a tolerance interval (TI); Transformed Probability Content [Equation 15] providing limits (UTBL, LTBL) of tolerance intervals (TI) for technical parameters based on the transformed probability content [0016] is based on cutoff values ​​(ξL, ξR) and is based on a specified probability content (pc); If the test formula is not satisfied, the specified probability content (pc) is the transformed probability content [Equation 17] The method is used for the calculation of at least one limit (UTBL, LTBL) of a tolerance interval (TI) rather than

15. A method for evaluating a manufacturing process, comprising the steps of any one of claims 1 to 14, The method, wherein at least one limit (UTBL, LTBL) of the tolerance interval (TI) is compared with the limits of a specification (USL, LSL) interval for a manufactured product having the same structure as the sample item.

16. A computer program comprising computer readable program code portions which, when executed on a controller or processor (Pr), perform the method steps of any one of claims 1 to 15.

17. 1. A computing device comprising: a processor (Pr) configured to execute instructions; a memory (Mem) configured to store instructions and to store data used or generated during execution of the instructions; 17. A computer program according to claim 16. The computing device comprising:

Citation Information

Patent Citations

  • Improved methods and systems for mapping traffic forecasts for telematics and route guidance applications

    JP2004523852A

  • Associating Attributes with Network Addresses

    JP2016525834A

  • Apparatus for the injection moulding of containers in plastic material

    US20120251649A1

  • WO16269-6